Beactica Announces Drug Discovery Collaboration with Arrow Therapeutics
News Nov 13, 2007
Beactica AB has announced that it has entered into a drug discovery collaboration agreement with Arrow Therapeutics Ltd (London, UK) whereby Beactica will direct its characterization technology at selected Arrow compounds against a confidential target.
"We are very pleased to be working with Arrow" said Beactica's CEO, Dr Per Kallblad. "The company has a world-class reputation for conducting break through research in the antiviral field and we look forward to applying our technology on their targets."
CEO of Arrow Therapeutics, Dr Ken Powell, said "Working with Beactica provides us with an opportunity to apply a new technology that has already shown strong potential."
Old age is the greatest risk factor for many diseases, including Alzheimer's disease (AD) and cancer. Geroprotectors are a recently identified class of anti-aging compounds. New research has now identified a unique subclass of these compounds, dubbed geroneuroprotectors (GNPs), which are AD drug candidates and slow the aging process in mice.READ MORE